QPPV.COM KNOWLEDGE ASSESSMENT

Ibritumomab Tiuxetan: Classification, Mechanism, EU History and Pharmacovigilance

Test your understanding of the concepts covered by Ibritumomab Tiuxetan: Classification, Radioimmunotherapy, EU History and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the principal role of yttrium-90 in the therapeutic preparation?
Question 2 of 10 Which statement best distinguishes radiation safety assessment from clinical causality assessment?
Question 3 of 10 Why should a case report specify the isotope and administered activity rather than identify only ibritumomab tiuxetan?
Question 4 of 10 A secondary malignancy is diagnosed several years after treatment. Which assessment approach is most appropriate?
Question 5 of 10 Which records best support reconstruction of the product administered to a patient?
Question 6 of 10 Which set of variables best supports aggregate review of safety reports for ibritumomab tiuxetan?
Question 7 of 10 A historical record shows that a patient received indium-111-labelled material during the Zevalin workflow. Which interpretation is most appropriate?
Question 8 of 10 A safety database entry labels an exposure as “Zevalin” but does not state whether it involved indium-111 or yttrium-90. What is the main pharmacovigilance concern?
Question 9 of 10 Which patient and disease information is particularly useful when interpreting an ibritumomab tiuxetan safety case?
Question 10 of 10 Which conclusion about the historical regimen is best supported by the article?

Select an answer to continue.

QPPV.com